Clinical activity of irofulven in hormone refractory prostate cancer.

被引：0
|
作者：
Cvitkovic, E
Kahatt, C
Senzer, N
Tombal, B
Culine, S
Raymond, E
Alexandre, J
Weems, G
MacDonald, J
机构：
[1] Cvitkovic & Associes Consultants, Le Kremlin Bicetre, France
[2] Mary Crowley Med Res Ctr, US Oncol, Dallas, TX USA
[3] UCLC St Luc, Brussels, Belgium
[4] CRLC, Montpellier, France
[5] Inst Gustave Roussy, Villejuif, France
[6] Hop Cochin, F-75674 Paris, France
[7] MGI Pharma Inc, Bloomington, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4766
引用
收藏
页码：447S / 447S
页数：1
相关论文
共 50 条
  • [31] The management of hormone refractory prostate cancer
    Newling, DWW
    EUROPEAN UROLOGY, 1996, 29 : 69 - 74
  • [32] Chemotherapy for hormone refractory prostate cancer
    Smith, DC
    UROLOGIC CLINICS OF NORTH AMERICA, 1999, 26 (02) : 323 - +
  • [33] Overview: Hormone refractory prostate cancer
    Crawford, ED
    Rosenblum, M
    Ziada, AM
    Lange, PH
    UROLOGY, 1999, 54 (6A) : 1 - 7
  • [34] Mechanisms of androgen-refractory prostate cancer.
    Debes, JD
    Tindall, DJ
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15): : 1488 - 1490
  • [35] Salvage prostatectomy for radiation refractory prostate cancer.
    Slezak, JM
    Amling, CL
    Lerner, SE
    Martin, SK
    Blute, ML
    Zincke, H
    JOURNAL OF UROLOGY, 1998, 159 (05): : 337 - 337
  • [36] Randomized phase II trial of irofulven/prednisone, irofulven/capecitabine/prednisone, or mitoxantrone/prednisone in hormone refractory prostate cancer (HRPC) patients failing first-line docetaxel: preliminary results
    Hart, L.
    Hainsworth, J.
    Ciuleanu, T.
    Oudard, S.
    Berger, E.
    Alexandre, J.
    Chi, K.
    Ruether, D.
    Kahatt, C.
    MacDonald, J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 94 - 94
  • [37] Final results of a phase Ib/IIa study of phenoxodiol in hormone-refractory prostate cancer.
    Davies, R
    Tulloch, A
    Frydenberg, M
    Kelly, G
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9123S - 9123S
  • [38] Neuroendocrine markers as predictor of octreotide acetate therapy in patients with hormone-refractory prostate cancer.
    Acosta, S
    Kälkner, KM
    Thorsson, O
    Fredriksson, M
    Nilsson, A
    Gustavsson, B
    Elingsbo, M
    Stridsberg, M
    Abrahamsson, PA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 443S - 443S
  • [39] New therapeutic approaches for hormone refractory prostate cancer. Study AP46/06
    Rexer, H.
    ONKOLOGE, 2007, 13 (04): : 363 - 364
  • [40] Phase I/II study of taxane and estramustine with samarium in patients with hormone refractory prostate cancer.
    Arnsmeier, SL
    Spies, S
    Shervin, D
    Pins, M
    Bergan, RC
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 439S - 439S
12345